S&P 500   4,590.14 (+0.49%)
DOW   36,175.98 (+0.63%)
QQQ   389.33 (+0.13%)
AAPL   190.96 (+0.53%)
MSFT   372.88 (-1.59%)
META   324.19 (-0.90%)
GOOGL   131.44 (-0.82%)
AMZN   146.58 (+0.34%)
TSLA   237.40 (-1.12%)
NVDA   469.78 (+0.44%)
NIO   7.17 (-1.38%)
BABA   73.35 (-2.04%)
AMD   120.66 (-0.41%)
T   16.64 (+0.42%)
F   10.50 (+2.34%)
MU   75.88 (-0.32%)
CGC   0.59 (+5.29%)
GE   123.23 (+1.17%)
DIS   92.18 (-0.55%)
AMC   6.77 (+1.80%)
PFE   29.22 (-4.10%)
PYPL   58.97 (+2.36%)
XOM   103.81 (+1.04%)
S&P 500   4,590.14 (+0.49%)
DOW   36,175.98 (+0.63%)
QQQ   389.33 (+0.13%)
AAPL   190.96 (+0.53%)
MSFT   372.88 (-1.59%)
META   324.19 (-0.90%)
GOOGL   131.44 (-0.82%)
AMZN   146.58 (+0.34%)
TSLA   237.40 (-1.12%)
NVDA   469.78 (+0.44%)
NIO   7.17 (-1.38%)
BABA   73.35 (-2.04%)
AMD   120.66 (-0.41%)
T   16.64 (+0.42%)
F   10.50 (+2.34%)
MU   75.88 (-0.32%)
CGC   0.59 (+5.29%)
GE   123.23 (+1.17%)
DIS   92.18 (-0.55%)
AMC   6.77 (+1.80%)
PFE   29.22 (-4.10%)
PYPL   58.97 (+2.36%)
XOM   103.81 (+1.04%)
S&P 500   4,590.14 (+0.49%)
DOW   36,175.98 (+0.63%)
QQQ   389.33 (+0.13%)
AAPL   190.96 (+0.53%)
MSFT   372.88 (-1.59%)
META   324.19 (-0.90%)
GOOGL   131.44 (-0.82%)
AMZN   146.58 (+0.34%)
TSLA   237.40 (-1.12%)
NVDA   469.78 (+0.44%)
NIO   7.17 (-1.38%)
BABA   73.35 (-2.04%)
AMD   120.66 (-0.41%)
T   16.64 (+0.42%)
F   10.50 (+2.34%)
MU   75.88 (-0.32%)
CGC   0.59 (+5.29%)
GE   123.23 (+1.17%)
DIS   92.18 (-0.55%)
AMC   6.77 (+1.80%)
PFE   29.22 (-4.10%)
PYPL   58.97 (+2.36%)
XOM   103.81 (+1.04%)
S&P 500   4,590.14 (+0.49%)
DOW   36,175.98 (+0.63%)
QQQ   389.33 (+0.13%)
AAPL   190.96 (+0.53%)
MSFT   372.88 (-1.59%)
META   324.19 (-0.90%)
GOOGL   131.44 (-0.82%)
AMZN   146.58 (+0.34%)
TSLA   237.40 (-1.12%)
NVDA   469.78 (+0.44%)
NIO   7.17 (-1.38%)
BABA   73.35 (-2.04%)
AMD   120.66 (-0.41%)
T   16.64 (+0.42%)
F   10.50 (+2.34%)
MU   75.88 (-0.32%)
CGC   0.59 (+5.29%)
GE   123.23 (+1.17%)
DIS   92.18 (-0.55%)
AMC   6.77 (+1.80%)
PFE   29.22 (-4.10%)
PYPL   58.97 (+2.36%)
XOM   103.81 (+1.04%)

Abcam Stock Price, News & Analysis (NASDAQ:ABCM)

$23.97
0.00 (0.00%)
(As of 11:57 AM ET)
Compare
Today's Range
$23.96
$23.98
50-Day Range
$22.55
$23.97
52-Week Range
$12.48
$25.32
Volume
4.12 million shs
Average Volume
3.04 million shs
Market Capitalization
$5.50 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$23.00

Abcam MarketRank™ Stock Analysis

Analyst Rating
Hold
2.17 Rating Score
Upside/​Downside
4.0% Downside
$23.00 Price Target
Short Interest
Healthy
2.43% of Shares Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
0.43mentions of Abcam in the last 14 days
Based on 4 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
29.55%
From $0.44 to $0.57 Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

1.57 out of 5 stars

Medical Sector

874th out of 948 stocks

Biological Products, Except Diagnostic Industry

155th out of 164 stocks


ABCM stock logo

About Abcam Stock (NASDAQ:ABCM)

Abcam plc, a life science company, focuses on identifying, developing, and distributing reagents and tools for scientific research, diagnostics, and drug discovery. The company's principal products include primary and secondary antibodies; conjugated antibodies and conjugation kits; singleplex immunoassays; proteins and peptides that include cytokines; edited cell lines and lysates; and various other products, including cellular activity kits, biochemicals, and cell signaling pathway tools. It serves scientists and researchers in academic institutions and research institutes, as well as in pharmaceutical, biotechnology, and diagnostics companies. The company has operations in the Americas, Europe, the Middle East, Africa, China, Japan, and rest of the Asia Pacific. It sells its products online. The company was incorporated in 1998 and is headquartered in Cambridge, the United Kingdom.

ABCM Stock Price History

ABCM Stock News Headlines

Abcam plc (NASDAQ:ABCM) Sees Large Growth in Short Interest
Trading Experts Call It “The Perfect Tesla Trade”
Thanks to a new discovery linked to shares of Tesla, regular folks can now target gains of 100% or more in six days or less. New research shows it’s happened 23 different times this year. The next trade is scheduled for this Thursday.
Abcam-Danaher Deal Receives All Identified Clearances - Quick Facts
Is Gold Really Boring?
Many investors perceive gold as a "boring" investment. But according to MoneyWeek, that's a good thing. Gold helps investors sleep soundly as it preserves wealth and creates a hedge against inflation. Today, there's a unique way to invest in gold, with real advantages over coins and mining stocks.
Jonathan Milner Issues Statement Responding to ISS Report
Abcam (ABCM) Gets a Hold from RBC Capital
ABCAM INVESTOR ALERT by the Former Attorney...
See More Headlines
Receive ABCM Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Abcam and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Today
12/01/2023
Fiscal Year End
12/31/2023

Industry, Sector and Symbol

Industry
Biological products, except diagnostic
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:ABCM
Fax
N/A
Employees
1,760
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$23.00
High Stock Price Target
$23.00
Low Stock Price Target
$23.00
Potential Upside/Downside
-4.0%
Consensus Rating
Hold
Rating Score (0-4)
2.17
Research Coverage
6 Analysts

Profitability

Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
$447.49 million
Cash Flow
$0.60 per share
Book Value
$3.92 per share

Miscellaneous

Free Float
213,842,000
Market Cap
$5.50 billion
Optionable
Not Optionable
Beta
0.89
20 Stocks to Sell Now Cover

MarketBeat has just released its list of 20 stocks that Wall Street analysts hate. These companies may appear to have good fundamentals, but top analysts smell something seriously rotten. Are any of these companies lurking around your portfolio? Find out by clicking the link below.

Get This Free Report

Key Executives

  • Mr. Alan Thomas Hirzel BS (Age 55)
    M.B.A., M.S., CEO & Executive Director
    Comp: $1.15M
  • Mr. Michael Shaun Baldock B.A. (Age 59)
    CFO & Director
    Comp: $850.65k
  • Marc Leigh Russell Perkins
    General Counsel & Company Secretary
  • Emma Sceats
    Senior Vice President of Sales & Marketing
  • Mr. Nick Skinner
    Senior Vice President of Human Resources
  • Ms. Alejandra Solache Ph.D.
    Senior Vice President of Research & Development
  • Mr. John Baker
    Senior Vice President of Supply Chain & Manufacturing
  • Juan Carlos Sacristan
    Senior Vice President of Data & Digital














ABCM Stock Analysis - Frequently Asked Questions

Should I buy or sell Abcam stock right now?

6 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Abcam in the last twelve months. There are currently 5 hold ratings and 1 buy rating for the stock. The consensus among Wall Street analysts is that investors should "hold" ABCM shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in ABCM, but not buy additional shares or sell existing shares.
View ABCM analyst ratings
or view top-rated stocks.

What is Abcam's stock price target for 2024?

6 equities research analysts have issued 12-month target prices for Abcam's stock. Their ABCM share price targets range from $23.00 to $23.00. On average, they expect the company's share price to reach $23.00 in the next twelve months. This suggests that the stock has a possible downside of 4.0%.
View analysts price targets for ABCM
or view top-rated stocks among Wall Street analysts.

How have ABCM shares performed in 2023?

Abcam's stock was trading at $15.56 at the beginning of the year. Since then, ABCM shares have increased by 54.0% and is now trading at $23.97.
View the best growth stocks for 2023 here
.

Are investors shorting Abcam?

Abcam saw a increase in short interest during the month of November. As of November 15th, there was short interest totaling 5,580,000 shares, an increase of 36.8% from the October 31st total of 4,080,000 shares. Based on an average daily volume of 7,370,000 shares, the days-to-cover ratio is presently 0.8 days.
View Abcam's Short Interest
.

What ETFs hold Abcam's stock?
When did Abcam IPO?

(ABCM) raised $149 million in an IPO on Thursday, October 22nd 2020. The company issued 9,000,000 shares at $16.52 per share. Morgan Stanley, BofA Securities, SVB Leerink, Lazard and William Blair acted as the underwriters for the IPO.

Who are Abcam's major shareholders?

Abcam's stock is owned by many different institutional and retail investors. Top institutional investors include Baillie Gifford & Co. (3.19%), Soros Fund Management LLC (2.70%), JPMorgan Chase & Co. (2.64%), Brown Advisory Inc. (2.25%), KRYGER CAPITAL Ltd (2.04%) and Pentwater Capital Management LP (1.88%).

How do I buy shares of Abcam?

Shares of ABCM stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

This page (NASDAQ:ABCM) was last updated on 12/1/2023 by MarketBeat.com Staff

My Account -